Nasopharyngeal Carcinoma
Conditions
Keywords
Nasopharyngeal Carcinoma, ovarian function, Pregnancy outcomes
Brief summary
This is an observational cohort study aimed to explore the fertility concerns, fertility preservation strategies, fertility status (pregnancy and Ovarian Failure) and birth outcome among young woman Nasopharyngeal carcinoma patients.
Detailed description
The purpose of this study was to explore the effects of radiotherapy and chemotherapy on ovarian function and pregnancy outcome after treatment in female survivors of non-metastatic nasopharyngeal carcinoma, so as to clarify the relationship between ovarian dysfunction after treatment and pregnancy outcome, as well as clarify the relationship between pregnancy after treatment and tumour progression.
Interventions
None listed
Sponsors
Sun Yat-sen University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 45 Years
Inclusion criteria
1. Patients with newly histologically confirmed non-keratinizing nasopharyngeal carcinoma, including WHO II or III ,with no distant metastasis 2. Age between 18-45, female 3. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1 4. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5×upper limit of normal (ULN),serum total bilirubin (TBIL) ≤2.0 times the upper limit of normal (ULN) . 5. Adequate renal function: creatinine clearance rate≥60 ml/min or Creatinine ≤1.5× upper limit of normal value. 6. No history of infertility. 7. No history of hysterectomy or bilateral ovariectomy. 8. Patient have signed on the informed consent, and well understood the objective and procedure of this study
Exclusion criteria
1. Histologically or cytologically confirmed with keratinizing squamous cell carcinoma of the nasopharynx. 2. Women in the period of pregnancy, lactation, or reproductive without effective contraceptive measures. 3. Known history of other malignancies (except cured basal cell carcinoma or carcinoma in situ of the cervix). 4. Patients with severe dysfunction of heart, liver, lung, kidney or marrow. 5. Patients with severe, uncontrolled disease or infections. 6. Refuse or fail to sign the informed consent . 7. Patients with personality or mental disorders, incapacity or limited capacity for civil conduct.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Premature Ovarian Failure (POF) | 3 years after Radiotherapy | Premature Ovarian Failure (POF) was defined as menopause before age 40 years. Menopause was defined as cessation of menstruation at least 1 year before the date of the survey in the absence of pregnancy, breastfeeding, continuous use of progestagens or other medication causing amenorrhea, or surgical removal of uterus and/ or ovaries. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progress-Free Survival (PFS) | 3 years after Radiotherapy | Progress-free survival is calculated from the date of registration to the date of the first progress at any site. |
| Pregnancy and birth outcome | Within 6 month of diagnosis, or 3-5years after Radiotherapy | The pregnancy history and pregnancy outcome of female Nasopharyngeal carcinoma (NPC) patients before diagnosis of NPC would be investigate Within 6 months of diagnosis. The pregnancy events and birth outcome of female NPC patients after diagnosis of NPC would be investigate among 3 to 5years after Radiotherapy. |
| Overall Survival (OS) | 3 years after Radiotherapy | The Overall Survival (OS) was defined as the duration from the date of registration assignment to the date of death from any cause or censored at the date of the last follow-up. |
| Locoregional Relapse-Free Survival (LRFS) | 3 years after Radiotherapy | The Locoregional Relapse-Free Survival (LRFS) is evaluated and calculated from the date of registration until the day of first locoregional relapse or until the date of the last follow-up visit |
| Distant Metastasis-Free Survival (DMFS) | 3 years after Radiotherapy | The DMFS is evaluated and calculated from the date of registration until the day of first distant metastases or until the date of the last follow-up visit. |
Countries
China
Contacts
Primary ContactHaiqiang Mai, MD, PhD
Backup ContactQiuyan Chen, MD, PhD
Outcome results
None listed